Core Insights - Edwards Lifesciences (EW) has achieved a remarkable 22.1% return over the past year, significantly outperforming the industry's decline of 3.8% and closely aligning with the S&P 500's rise of 23.5% [1][8] Company Performance - The company is currently ranked 2 (Buy) by Zacks and has shown consistent growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, while effectively scaling its fast-growing businesses [2] - The Transcatheter Aortic Valve Replacement (TAVR) platform has benefited from technological advancements like RESILIA and increased global adoption, with TAVR sales exceeding $1 billion for the fifth consecutive quarter [2][6] - The Surgical Structural Heart business is experiencing robust uptake of premium surgical technologies globally, contributing to overall growth [2][10] Recent Developments - On September 3, 2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson, and Company for $4.2 billion, enhancing its balance sheet flexibility for investments in new technologies [3] - The company has seen strong momentum in the TMTT segment, driven by the global adoption of PASCAL and EVOQUE systems, which provide solutions for mitral and tricuspid patients [4][8] - The EVOQUE system became eligible for all Medicare beneficiaries with symptomatic tricuspid regurgitation in March 2025, and the SAPIEN M3 mitral valve replacement system received CE Mark approval in April 2025 [5] Financial Estimates - The Zacks Consensus Estimate projects a 14.8% increase in earnings per share (EPS) for 2026 to $2.94 and a 12.2% increase for 2027 to $3.30, with revenues expected to grow 9.6% to $6.65 billion in 2026 and 9.8% to $7.30 billion in 2027 [12]